scube2 Antibody

What is the molecular structure of SCUBE2 and which domains should researchers target for antibody selection?

SCUBE2 is a 999 amino acid protein that belongs to the evolutionarily conserved SCUBE family. Its structure consists of multiple functional domains including:

• N-terminal signal peptide for secretion

• Nine EGF-like domains

• Spacer domain

• Cysteine-rich domain

• C-terminal CUB domain

For antibody selection, researchers should consider the specific domain relevant to their research question. C-terminal antibodies are commonly used for detection of the full-length protein, while antibodies targeting specific domains may be useful for investigating domain-specific functions. The protein can form homo-oligomers and hetero-oligomers with other SCUBE family members, specifically SCUBE1 and SCUBE3 .

What is the expression pattern of SCUBE2 in normal and cancerous tissues?

In normal tissues, SCUBE2 is widely expressed across adult tissues. Immunohistochemistry studies have shown that SCUBE2 is mainly expressed in:

• Vascular endothelial cells

• Mammary ductal epithelial cells in normal breast tissue

In cancer contexts, SCUBE2 shows variable expression:

• Positive SCUBE2 protein staining observed in 55% (86 of 156) of primary breast tumors

• Low expression in glioma tissue and cell lines

• Reduced expression often correlates with cancer progression in breast cancer

Patients with SCUBE2-positive expressing tumors have been shown to have better prognosis than those with SCUBE2-negative tumors in terms of disease-free survival .

What types of SCUBE2 antibodies are available and how should researchers select the appropriate one for their experiments?

Several types of SCUBE2 antibodies are available for research purposes:

Selection criteria should include:

• Experimental application (Western blot, immunoprecipitation, immunofluorescence)

• Target species (human samples vs. animal models)

• Target region of interest (based on research hypothesis)

• Need for conjugated antibodies (HRP, FITC, PE, or other labels for specific applications)

Researchers should validate antibody specificity using positive controls and consider cross-reactivity with other SCUBE family members .

What are the methodological considerations for optimizing Western blotting with SCUBE2 antibodies?

For optimal Western blotting results with SCUBE2 antibodies:

• Sample preparation:

  • Use fresh tissue or cell lysates

  • Include appropriate controls (cell lines with known SCUBE2 expression)

  • Consider using denaturing conditions that preserve the epitope structure

• Gel electrophoresis and transfer:

  • Use appropriate percentage gels based on SCUBE2 molecular weight (approximately 110 kDa)

  • Optimize transfer conditions for large proteins

• Blocking and antibody incubation:

  • Test different blocking agents (BSA vs. non-fat milk)

  • Optimize primary antibody dilution (typically 1:500 to 1:2000)

  • Incubate at 4°C overnight for better specificity

• Detection considerations:

  • Secondary antibody selection should match the host species of primary antibody

  • Consider enhanced chemiluminescence for higher sensitivity

Each antibody has been validated under specific conditions, so researchers should consult the manufacturer's recommendations and optimize based on their experimental system .

How does SCUBE2 affect cancer cell biology and what experimental approaches are recommended to study these effects?

SCUBE2 has been shown to influence cancer cell biology in multiple ways:

• Cell proliferation:

  • Overexpression of SCUBE2 suppresses MCF-7 breast cancer cell proliferation

  • SCUBE2 overexpression inhibits glioma cell proliferation both in vitro and in vivo

  • Recommended approach: MTT assays and colony formation assays

• Migration and invasion:

  • SCUBE2 overexpression markedly attenuates migratory and invasive abilities of glioma cells (U87 and A172)

  • Recommended approach: Transwell migration and invasion assays

• Tumor growth in vivo:

  • SCUBE2 overexpression reduces MCF-7 xenograft tumor growth in nude mice

  • Similar results observed in glioma xenograft models

  • Recommended approach: Subcutaneous xenograft models with tumor volume and weight measurements

For comprehensive studies, researchers should consider both in vitro functional assays and in vivo xenograft models to understand the multifaceted roles of SCUBE2 in cancer.

What is the prognostic significance of SCUBE2 in cancer and how can researchers effectively study this relationship?

SCUBE2 has emerged as a potential prognostic biomarker in cancer:

• Breast cancer prognosis:

  • Patients with SCUBE2-positive tumors show better disease-free survival

  • Multivariate analysis confirmed SCUBE2 protein expression as an independent prognostic factor

  • High SCUBE2 expression may predict resistance to taxane-based neoadjuvant chemotherapy, particularly in ER-positive/HER2-negative breast cancers

• Methodological approaches for prognostic studies:

  • Immunohistochemistry of tumor tissue microarrays with standardized scoring

  • Correlation of SCUBE2 expression with clinical outcomes (survival analysis)

  • Integration with other molecular markers (ER, PR, HER2) for comprehensive analysis

  • Gene expression analysis in large cohorts with long-term follow-up data

• Recommended statistical approaches:

  • Kaplan-Meier survival analysis with log-rank tests

  • Cox proportional hazards models for multivariate analysis

  • Receiver operating characteristic (ROC) curve analysis for predictive value assessment

Recent studies suggest SCUBE2 has predictive strength comparable to ESR1 in ER-positive/HER2-negative breast cancer patients and higher predictive ability in ER-positive and HER2-positive breast cancers .

How does SCUBE2 interact with the Hedgehog signaling pathway and what experimental approaches can elucidate this relationship?

SCUBE2 functions as a novel component of the Hedgehog signaling pathway:

• Molecular interactions:

  • SCUBE2 acts as an adaptor that connects Sonic Hedgehog (Shh) sheddases with their substrates

  • "Mini-Scube2" lacking all EGF domains remains functional, while Scube2Δ lacking cysteine-rich and CUB domains is inactive

  • The isolated spacer and CUB domains appear to compete with the adaptor activity

• Functional significance:

  • The Hedgehog signal is essential for the induction of ventral neuronal and muscle cell types during vertebrate development

  • Shh signaling pathway involvement has been implicated in the inhibitory effect of SCUBE2 overexpression on glioma cells

• Recommended experimental approaches:

  • Co-immunoprecipitation assays to detect protein-protein interactions

  • Mutagenesis studies of specific domains to identify critical regions

  • Reporter assays for Hedgehog pathway activation

  • RNA interference to validate pathway components

  • Pharmacological inhibitors of Hedgehog signaling combined with SCUBE2 manipulation

Previous experiments demonstrated that SCUBE2 does not form stable complexes with Shh in solution, as 5E1/PA beads immunoprecipitated Shh, but wild-type or mutant SCUBE2 was not co-immunoprecipitated .

What are the molecular mechanisms by which SCUBE2 suppresses tumor growth and what experimental approaches can resolve contradictory findings?

The tumor-suppressive effects of SCUBE2 involve multiple molecular mechanisms:

• Bone morphogenetic protein (BMP) antagonism:

  • The C-terminal region of SCUBE2 directly binds to and antagonizes BMP activity

  • This mechanism may contribute to growth suppression in breast cancer

• Cell cycle regulation:

  • Potential interaction with cell cycle regulators (suggested by association with CCND1)

  • Experimental approach: Cell cycle analysis by flow cytometry and expression analysis of cell cycle regulators

• Experimental approaches to resolve contradictory findings:

  • Tissue-specific knockout or knockdown models

  • Context-dependent analysis (considering microenvironment factors)

  • Single-cell analysis to identify heterogeneous responses

  • Comparative studies across different cancer types

  • Integration of in vitro and in vivo findings

• Recommended techniques for mechanistic studies:

  • CRISPR/Cas9-mediated genome editing

  • ChIP-seq for transcriptional regulation analysis

  • Proteomic approaches to identify interaction partners

  • Phospho-proteomic analysis to identify signaling pathway alterations

These approaches can help reconcile findings of SCUBE2 as a tumor suppressor in breast cancer but potentially having different roles in other cancer contexts .

How can SCUBE2 be leveraged as a therapeutic target or biomarker in cancer, and what experimental approaches are most promising?

SCUBE2 shows potential as both a biomarker and therapeutic target:

• As a biomarker:

  • Predictive marker for response to taxane-based neoadjuvant chemotherapy

  • Prognostic marker in breast cancer (independent of other factors)

  • Experimental approach: Validation in large clinical cohorts with standardized detection methods

• As a therapeutic target:

  • Potential for gene therapy approaches to restore SCUBE2 expression

  • Targeting SCUBE2's role in Hedgehog signaling

  • Development of peptide mimetics based on functional domains

  • Experimental approaches: Viral vector-mediated expression, peptide screening, small molecule screening

• Data from network analysis:

  • SCUBE2 was found among seventeen upregulated genes associated with resistance to taxane-based neoadjuvant therapy

  • ESR1, CCND1, and SCUBE2 emerged as the top three key genes associated with resistance

  • SCUBE2 displayed high predictive power comparable to ESR1 and better than CCND1

• Recommended validation approaches:

  • Patient-derived xenograft models

  • Ex vivo tumor slice cultures

  • Combination therapy studies with existing treatments

  • Correlative analysis in clinical trials

Emerging evidence about SCUBE2's role as a coreceptor involved in tumor progression and angiogenesis further supports its potential as a therapeutic target .

What technical challenges exist in studying SCUBE2 as a potential therapeutic target and how can researchers address them?

Several technical challenges must be addressed when studying SCUBE2 as a therapeutic target:

• Protein structure complexity:

  • Multiple functional domains create challenges for targeting specific interactions

  • Solution: Domain-specific antibodies or peptides targeting critical interaction surfaces

  • Structural biology approaches (crystallography, cryo-EM) to guide rational drug design

• Context-dependent effects:

  • Different roles in different cancer types or cellular contexts

  • Solution: Comprehensive profiling across cancer types and subtypes

  • Cell type-specific conditional models in vivo

• Technical limitations of detection:

  • Sensitivity and specificity issues with available antibodies

  • Solution: Validation across multiple antibodies and detection methods

  • Development of more specific monoclonal antibodies for research and potential therapeutic use

• Translational barriers:

  • Gap between preclinical findings and clinical applications

  • Solution: Biomarker-driven clinical trial designs

  • Patient stratification based on SCUBE2 status

  • Development of companion diagnostics alongside therapeutic approaches

Addressing these challenges requires multidisciplinary approaches and integration of various experimental systems to fully understand and leverage SCUBE2's potential as a therapeutic target in cancer .